1. Scrip

Novartis Changing Of The Guard Continues As R&D Chief Bradner Exits

Merck & Co’s Marshall To Take Over

 
• By Andrew McConaghie

A smooth handover hints at an amicable departure for Jay Bradner, but also gives CEO Vas Narasimhan the chance to refresh strategy with a new team.

Novartis NIBR Cambridge, MA
Bradner has headed up the Cambridge, MA-headquartered NIBR since 2016, but will hand over to Fiona Marshall in November. • Source: Shutterstock

Jay Bradner is to leave Novartis after seven years as its leader of drug discovery, a departure which will add to a changing of the guard already underway at the Swiss-headquartered pharma company.

He will depart from the role of president of the Novartis Institutes for BioMedical Research (NIBR), on 31 October with his replacement - current Merck & Co

More from Immunological

More from Therapy Areas